company background image
RGNX

REGENXBIO NasdaqGS:RGNX Stock Report

Last Price

US$33.37

Market Cap

US$1.4b

7D

-4.8%

1Y

6.2%

Updated

12 Aug, 2022

Data

Company Financials +
RGNX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends0/6

RGNX Stock Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease.

REGENXBIO Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for REGENXBIO
Historical stock prices
Current Share PriceUS$33.37
52 Week HighUS$46.46
52 Week LowUS$18.69
Beta1.07
1 Month Change11.46%
3 Month Change60.12%
1 Year Change6.17%
3 Year Change-10.25%
5 Year Change67.27%
Change since IPO9.59%

Recent News & Updates

Aug 03

Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%

Regenxbio (NASDAQ:RGNX) on Wednesday said it intends to file a biologics license application (BLA) in 2024 using the U.S. FDA's accelerated approval process for its RGX-121 treatment candidate for Mucopolysaccharidosis Type II (MPS II). Shares of the clinical-stage biotech were 8% higher at $34.34 in early trading. The company is slated to report Q2 results after market close. MPS II, also known as Hunter Syndrome, is a hereditary metabolic disease in which the body is missing or does not have enough of an enzyme needed to break down long chains of sugar molecules. The FDA's accelerated approval program allows for the expedited development and review of drugs that treat serious conditions. RGNX said its ongoing phase 1/2 trial of RGX-121 in children up to five years old had been expanded into an active pivotal phase 1/2/3 trial and was enrolling patients. Preliminary results from the early-to-mid stage trial of RGX-121 in Feb. showed that it continued to be well-tolerated with dose-dependent reductions of glycosaminoglycans in the cerebrospinal fluid.

Shareholder Returns

RGNXUS BiotechsUS Market
7D-4.8%1.2%3.2%
1Y6.2%-21.7%-10.1%

Return vs Industry: RGNX exceeded the US Biotechs industry which returned -23% over the past year.

Return vs Market: RGNX exceeded the US Market which returned -11.7% over the past year.

Price Volatility

Is RGNX's price volatile compared to industry and market?
RGNX volatility
RGNX Average Weekly Movement8.7%
Biotechs Industry Average Movement12.5%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: RGNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: RGNX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008372Ken Millshttps://www.regenxbio.com

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.

REGENXBIO Inc. Fundamentals Summary

How do REGENXBIO's earnings and revenue compare to its market cap?
RGNX fundamental statistics
Market CapUS$1.44b
Earnings (TTM)US$90.72m
Revenue (TTM)US$484.30m

15.9x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGNX income statement (TTM)
RevenueUS$484.30m
Cost of RevenueUS$247.27m
Gross ProfitUS$237.03m
Other ExpensesUS$146.31m
EarningsUS$90.72m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.10
Gross Margin48.94%
Net Profit Margin18.73%
Debt/Equity Ratio0%

How did RGNX perform over the long term?

See historical performance and comparison